The bioT3 Platform

Ralph V. Boccia, MD, FACP

Video Categories: PMO Interview with the Innovator Series: Volume 9

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
July 29, 2015

Personalized Medicine’s Impact on Cancer Care

Dr. Jorge Cortes provides examples of how personalized or precision medicine has positively impacted the approach to cancer care, citing the benefits of FLT3 inhibitors, IDH inhibitors, and MEK inhibitors, and other targeted treatments.

July 13, 2021

Recommendations for Mutational Analysis of Various Solid Tumors

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler Rush of University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain which targetable mutation should be screened for various solid tumors.